For these reasons, we propose to conduct a phase I/II study evaluating the tolerability and efficacy of [177Lu]Lu-PSMA-1 in patients with PSMA-positive metastatic ccRCC selected through [Ga68]Ga-PSMA PET. This evidence concerns the gene FOLH1 and nonpapillary renal cell carcinoma.